Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy
Abstract Background Thrombotic microangiopathy (TMA) is caused by various conditions, such as decreased a ADAMTS13 level, activated or injured vascular endothelial cells or activated platelets. This study examined the soluble platelet glycoprotein VI (sGPVI) levels in patients with TMA to evaluate t...
Gespeichert in:
| Veröffentlicht in: | Thrombosis research 2014-03, Vol.133 (3), p.440-444 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 444 |
|---|---|
| container_issue | 3 |
| container_start_page | 440 |
| container_title | Thrombosis research |
| container_volume | 133 |
| creator | Yamashita, Yoshiki Naitoh, Katsuki Wada, Hideo Ikejiri, Makoto Mastumoto, Takeshi Ohishi, Koshi Hosaka, Yoshitaka Nishikawa, Masakatsu Katayama, Naoyuki |
| description | Abstract Background Thrombotic microangiopathy (TMA) is caused by various conditions, such as decreased a ADAMTS13 level, activated or injured vascular endothelial cells or activated platelets. This study examined the soluble platelet glycoprotein VI (sGPVI) levels in patients with TMA to evaluate the activation of platelets in thrombotic states. Materials and Methods The plasma levels of sGPVI, ADAMTS13 activity, von Willebrand factor (VWF) and VWF propeptide (VWFpp) were measured in patients with TMA. Results The plasma levels of sGPVI were significantly higher in postoperative patients, patients with TMA and those with disseminated intravascular coagulation (DIC) than in those without thrombosis. The plasma levels of sGPVI were the highest in patients with TMA without markedly reduced ADAMTS13 and those were significantly reduced after plasma exchange. Conclusion The measurement of sGPVI level is therefore considered to be important for the diagnosis and evaluation of TMA. |
| doi_str_mv | 10.1016/j.thromres.2013.11.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1499153171</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0049384813005598</els_id><sourcerecordid>1499153171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-826e2d8bebe20e3af486449411fdad31b7a9a1695dbd4d34cd2b5b69828f656b3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhL1Q-lkNSfyVxLghUlbJSJZCAXi1_TLpenHiJva323-OwbQ9cOFkjPzPz6hmEziipKaHtxbbOmzmOM6SaEcprSmvC-Au0orLrKyY69hKtCBF9xaWQJ-hNSltCaEf75jU6YYKzRnbdCo1XAe51Bod3QadR41JCSDgOOMWwNwGWjwwBMr4LBxt3c8zgJ3y7xufX327X73Epdjp7mHLCDz5v8N9kJmZv8ejtHPV052NBNoe36NWgQ4J3j-8p-vn56sfll-rm6_X68tNNZRvS5UqyFpiTBgwwAlwPQrZC9ILSwWnHqel0r2nbN8444biwjpnGtL1kcmib1vBTdH6cW9L-3kPKavTJQgh6grhPioq-pw0vOgraHtESNKUZBrWb_ajng6JELarVVj2pVotqRakqqkvj2eOOvRnBPbc9uS3AxyNQfMK9h1klWyxZcH4Gm5WL_v87PvwzwgY_eavDLzhA2sb9PBWPiqrEFFHfl4Mv96ackKbpJf8DTk2qHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1499153171</pqid></control><display><type>article</type><title>Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Yamashita, Yoshiki ; Naitoh, Katsuki ; Wada, Hideo ; Ikejiri, Makoto ; Mastumoto, Takeshi ; Ohishi, Koshi ; Hosaka, Yoshitaka ; Nishikawa, Masakatsu ; Katayama, Naoyuki</creator><creatorcontrib>Yamashita, Yoshiki ; Naitoh, Katsuki ; Wada, Hideo ; Ikejiri, Makoto ; Mastumoto, Takeshi ; Ohishi, Koshi ; Hosaka, Yoshitaka ; Nishikawa, Masakatsu ; Katayama, Naoyuki</creatorcontrib><description>Abstract Background Thrombotic microangiopathy (TMA) is caused by various conditions, such as decreased a ADAMTS13 level, activated or injured vascular endothelial cells or activated platelets. This study examined the soluble platelet glycoprotein VI (sGPVI) levels in patients with TMA to evaluate the activation of platelets in thrombotic states. Materials and Methods The plasma levels of sGPVI, ADAMTS13 activity, von Willebrand factor (VWF) and VWF propeptide (VWFpp) were measured in patients with TMA. Results The plasma levels of sGPVI were significantly higher in postoperative patients, patients with TMA and those with disseminated intravascular coagulation (DIC) than in those without thrombosis. The plasma levels of sGPVI were the highest in patients with TMA without markedly reduced ADAMTS13 and those were significantly reduced after plasma exchange. Conclusion The measurement of sGPVI level is therefore considered to be important for the diagnosis and evaluation of TMA.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/j.thromres.2013.11.023</identifier><identifier>PMID: 24325877</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>ADAM Proteins - blood ; ADAMTS13 ; ADAMTS13 Protein ; Adult ; Blood Platelets - metabolism ; Blotting, Western ; Case-Control Studies ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Immunoprecipitation ; Male ; Middle Aged ; Platelet Activation ; Platelet Membrane Glycoproteins - metabolism ; sGPVI ; Thrombotic Microangiopathies - blood ; TMA ; von Willebrand Factor - metabolism ; Young Adult</subject><ispartof>Thrombosis research, 2014-03, Vol.133 (3), p.440-444</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-826e2d8bebe20e3af486449411fdad31b7a9a1695dbd4d34cd2b5b69828f656b3</citedby><cites>FETCH-LOGICAL-c507t-826e2d8bebe20e3af486449411fdad31b7a9a1695dbd4d34cd2b5b69828f656b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.thromres.2013.11.023$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24325877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamashita, Yoshiki</creatorcontrib><creatorcontrib>Naitoh, Katsuki</creatorcontrib><creatorcontrib>Wada, Hideo</creatorcontrib><creatorcontrib>Ikejiri, Makoto</creatorcontrib><creatorcontrib>Mastumoto, Takeshi</creatorcontrib><creatorcontrib>Ohishi, Koshi</creatorcontrib><creatorcontrib>Hosaka, Yoshitaka</creatorcontrib><creatorcontrib>Nishikawa, Masakatsu</creatorcontrib><creatorcontrib>Katayama, Naoyuki</creatorcontrib><title>Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>Abstract Background Thrombotic microangiopathy (TMA) is caused by various conditions, such as decreased a ADAMTS13 level, activated or injured vascular endothelial cells or activated platelets. This study examined the soluble platelet glycoprotein VI (sGPVI) levels in patients with TMA to evaluate the activation of platelets in thrombotic states. Materials and Methods The plasma levels of sGPVI, ADAMTS13 activity, von Willebrand factor (VWF) and VWF propeptide (VWFpp) were measured in patients with TMA. Results The plasma levels of sGPVI were significantly higher in postoperative patients, patients with TMA and those with disseminated intravascular coagulation (DIC) than in those without thrombosis. The plasma levels of sGPVI were the highest in patients with TMA without markedly reduced ADAMTS13 and those were significantly reduced after plasma exchange. Conclusion The measurement of sGPVI level is therefore considered to be important for the diagnosis and evaluation of TMA.</description><subject>ADAM Proteins - blood</subject><subject>ADAMTS13</subject><subject>ADAMTS13 Protein</subject><subject>Adult</subject><subject>Blood Platelets - metabolism</subject><subject>Blotting, Western</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immunoprecipitation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Platelet Activation</subject><subject>Platelet Membrane Glycoproteins - metabolism</subject><subject>sGPVI</subject><subject>Thrombotic Microangiopathies - blood</subject><subject>TMA</subject><subject>von Willebrand Factor - metabolism</subject><subject>Young Adult</subject><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EokvhL1Q-lkNSfyVxLghUlbJSJZCAXi1_TLpenHiJva323-OwbQ9cOFkjPzPz6hmEziipKaHtxbbOmzmOM6SaEcprSmvC-Au0orLrKyY69hKtCBF9xaWQJ-hNSltCaEf75jU6YYKzRnbdCo1XAe51Bod3QadR41JCSDgOOMWwNwGWjwwBMr4LBxt3c8zgJ3y7xufX327X73Epdjp7mHLCDz5v8N9kJmZv8ejtHPV052NBNoe36NWgQ4J3j-8p-vn56sfll-rm6_X68tNNZRvS5UqyFpiTBgwwAlwPQrZC9ILSwWnHqel0r2nbN8444biwjpnGtL1kcmib1vBTdH6cW9L-3kPKavTJQgh6grhPioq-pw0vOgraHtESNKUZBrWb_ajng6JELarVVj2pVotqRakqqkvj2eOOvRnBPbc9uS3AxyNQfMK9h1klWyxZcH4Gm5WL_v87PvwzwgY_eavDLzhA2sb9PBWPiqrEFFHfl4Mv96ackKbpJf8DTk2qHw</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Yamashita, Yoshiki</creator><creator>Naitoh, Katsuki</creator><creator>Wada, Hideo</creator><creator>Ikejiri, Makoto</creator><creator>Mastumoto, Takeshi</creator><creator>Ohishi, Koshi</creator><creator>Hosaka, Yoshitaka</creator><creator>Nishikawa, Masakatsu</creator><creator>Katayama, Naoyuki</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140301</creationdate><title>Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy</title><author>Yamashita, Yoshiki ; Naitoh, Katsuki ; Wada, Hideo ; Ikejiri, Makoto ; Mastumoto, Takeshi ; Ohishi, Koshi ; Hosaka, Yoshitaka ; Nishikawa, Masakatsu ; Katayama, Naoyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-826e2d8bebe20e3af486449411fdad31b7a9a1695dbd4d34cd2b5b69828f656b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>ADAM Proteins - blood</topic><topic>ADAMTS13</topic><topic>ADAMTS13 Protein</topic><topic>Adult</topic><topic>Blood Platelets - metabolism</topic><topic>Blotting, Western</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immunoprecipitation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Platelet Activation</topic><topic>Platelet Membrane Glycoproteins - metabolism</topic><topic>sGPVI</topic><topic>Thrombotic Microangiopathies - blood</topic><topic>TMA</topic><topic>von Willebrand Factor - metabolism</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamashita, Yoshiki</creatorcontrib><creatorcontrib>Naitoh, Katsuki</creatorcontrib><creatorcontrib>Wada, Hideo</creatorcontrib><creatorcontrib>Ikejiri, Makoto</creatorcontrib><creatorcontrib>Mastumoto, Takeshi</creatorcontrib><creatorcontrib>Ohishi, Koshi</creatorcontrib><creatorcontrib>Hosaka, Yoshitaka</creatorcontrib><creatorcontrib>Nishikawa, Masakatsu</creatorcontrib><creatorcontrib>Katayama, Naoyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamashita, Yoshiki</au><au>Naitoh, Katsuki</au><au>Wada, Hideo</au><au>Ikejiri, Makoto</au><au>Mastumoto, Takeshi</au><au>Ohishi, Koshi</au><au>Hosaka, Yoshitaka</au><au>Nishikawa, Masakatsu</au><au>Katayama, Naoyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>133</volume><issue>3</issue><spage>440</spage><epage>444</epage><pages>440-444</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><abstract>Abstract Background Thrombotic microangiopathy (TMA) is caused by various conditions, such as decreased a ADAMTS13 level, activated or injured vascular endothelial cells or activated platelets. This study examined the soluble platelet glycoprotein VI (sGPVI) levels in patients with TMA to evaluate the activation of platelets in thrombotic states. Materials and Methods The plasma levels of sGPVI, ADAMTS13 activity, von Willebrand factor (VWF) and VWF propeptide (VWFpp) were measured in patients with TMA. Results The plasma levels of sGPVI were significantly higher in postoperative patients, patients with TMA and those with disseminated intravascular coagulation (DIC) than in those without thrombosis. The plasma levels of sGPVI were the highest in patients with TMA without markedly reduced ADAMTS13 and those were significantly reduced after plasma exchange. Conclusion The measurement of sGPVI level is therefore considered to be important for the diagnosis and evaluation of TMA.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>24325877</pmid><doi>10.1016/j.thromres.2013.11.023</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-3848 |
| ispartof | Thrombosis research, 2014-03, Vol.133 (3), p.440-444 |
| issn | 0049-3848 1879-2472 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1499153171 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | ADAM Proteins - blood ADAMTS13 ADAMTS13 Protein Adult Blood Platelets - metabolism Blotting, Western Case-Control Studies Female Hematology, Oncology and Palliative Medicine Humans Immunoprecipitation Male Middle Aged Platelet Activation Platelet Membrane Glycoproteins - metabolism sGPVI Thrombotic Microangiopathies - blood TMA von Willebrand Factor - metabolism Young Adult |
| title | Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A31%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20plasma%20levels%20of%20soluble%20platelet%20glycoprotein%20VI%20(GPVI)%20in%20patients%20with%20thrombotic%20microangiopathy&rft.jtitle=Thrombosis%20research&rft.au=Yamashita,%20Yoshiki&rft.date=2014-03-01&rft.volume=133&rft.issue=3&rft.spage=440&rft.epage=444&rft.pages=440-444&rft.issn=0049-3848&rft.eissn=1879-2472&rft_id=info:doi/10.1016/j.thromres.2013.11.023&rft_dat=%3Cproquest_cross%3E1499153171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1499153171&rft_id=info:pmid/24325877&rft_els_id=S0049384813005598&rfr_iscdi=true |